Hong Kong Beverage Stock News

FIT Hon Teng closed at HK$5.22, after a rough few months that left the stock down double digits over 7, 30 and 90 days. Yet the latest half year numbers tell a calmer story. Revenue sits in the multi billion US$ range and trailing twelve month earnings from continuing operations are in the mid US$100 million bracket, which is enough for the stock to trade on a premium P/E multiple versus Hong Kong electronics peers. The tension now is clear: sentiment has reset lower while the valuation still...

The market had Sundart Holdings priced like a problem stock coming into these results, with the shares at HK$0.66 and a P/E of 5.1x, far below peers. Yet the latest half year numbers tell a calmer story. Net income from continuing operations over the trailing twelve months sits at HK$283.3m, and earnings per share of HK$0.131 still support a high headline dividend yield of 7.58%. The real tension now is whether that income stream and dividend are sturdy enough, which helps explain why today’s...

HK Electric Investments came into this earnings season looking like a classic defensive utility, with the stock edging only about 1.3% higher over the past month and trading on a richer P/E multiple than many regional peers. The headline from the half year numbers is margin pressure. Trailing net profit margin sits at 25.2%, slightly below last year’s 26.3%, while debt remains poorly covered by operating cash flow. For a stock often treated as a steady income play, this mix of tight margins...

In August 2026, global markets have been buoyed by record highs in major U.S. stock indexes, driven by positive corporate earnings and enthusiasm for AI-related stocks. As investors navigate this optimistic yet complex landscape, identifying undervalued stocks becomes crucial to capitalizing on potential value opportunities amidst fluctuating economic indicators and geopolitical developments.

Ascletis Pharma (SEHK:1672) has drawn fresh attention after launching two Phase I obesity trials in the U.S. and starting a global Phase III program for its oral GLP-1 candidate ASC30. See our latest analysis for Ascletis Pharma. The recent obesity pipeline updates arrive after a mixed share price run for Ascletis Pharma. The stock rose 13.29% over a 7 day share price return but remains down 37.61% over a 90 day share price return and has recorded a 26.41% decline on the 1 year total...

Insiders who bought WK Group (Holdings) Limited ( HKG:2535 ) in the last 12 months may probably not pay attention to...

While Helens International Holdings Company Limited ( HKG:9869 ) might not have the largest market cap around , it saw...

From what we can see, insiders were net buyers in Gemini Investments (Holdings) Limited's ( HKG:174 ) during the past...

Last week, Launch Tech Company Limited ( HKG:2488 ) insiders, who had purchased shares in the previous 12 months were...

As Asian markets navigate a landscape marked by geopolitical developments and economic shifts, investors are increasingly looking for opportunities in stocks that may be priced below their intrinsic value. In such an environment, identifying undervalued stocks can be crucial for those aiming to capitalize on potential market inefficiencies and achieve long-term growth.

As Asian markets navigate a complex landscape marked by geopolitical developments and economic shifts, investors are increasingly looking beyond traditional blue-chip stocks for growth opportunities. Penny stocks, while often associated with smaller or newer companies, continue to capture attention as they offer potential for significant returns at lower price points. Despite being considered a somewhat outdated term, these investments can still present compelling opportunities when backed by...

Angelalign Technology (SEHK:6699) drew investor attention after issuing new earnings guidance for the six months to 30 June 2026, highlighting higher clear aligner volumes, revenue and net profit compared with the same period in 2025. See our latest analysis for Angelalign Technology. Angelalign Technology’s latest guidance comes after a strong run in the stock, with a 30-day share price return of 28.07% and year to date share price return of 54.35%. However, the 5-year total shareholder...

Why Brilliance China Automotive Holdings Stock Is Back in Focus Brilliance China Automotive Holdings (SEHK:1114) has drawn fresh attention after issuing unaudited guidance indicating that profit attributable to equity holders for the first half of 2026 may fall by up to 56% year on year. See our latest analysis for Brilliance China Automotive Holdings. Despite the weak profit guidance, Brilliance China Automotive Holdings has seen a short-term rebound, with a 1-month share price return of...

Board meeting puts Ubtech Robotics stock incentives in focus Ubtech Robotics (SEHK:9880) has called a board meeting for 10 August 2026 to consider proposing an H Share Incentive Scheme, drawing attention to how the company plans to reward and retain key employees. See our latest analysis for Ubtech Robotics. At a share price of HK$89.65, Ubtech Robotics has seen short term share price momentum pick up, with a 1 month share price return of 5.41%. However, the share price return year to date is...

Why Skyworth Group’s latest guidance is drawing investor attention Skyworth Group (SEHK:751) has issued earnings guidance for the six months to 30 June 2026, flagging an expected increase in unaudited consolidated net profit of at least 170% versus the same period in 2025. The company links this jump mainly to significant gains on certain equity securities tied to semiconductor sector valuations, as well as higher sales, revenue and gross profit margin for smart devices in its smart systems...

Akeso (SEHK:9926) has just reached a fresh clinical milestone. The company has dosed the first patient in a Phase II trial of its TROP2/Nectin-4 ADC AK146D1 in combination with ivonescimab for advanced breast cancer. See our latest analysis for Akeso. Akeso's latest trial update comes after a mixed period for the stock, with a 7 day share price return of 8.58% and a 30 day share price return of 4.78%, but a 90 day share price return that declined 19.95%. Over longer horizons, total...

Why BYD’s Latest Production and Sales Update Matters BYD (SEHK:1211) released unaudited July 2026 production and sales figures that show stronger monthly volumes than a year earlier, while year to date totals remain below the previous period. This gives investors mixed operational signals. See our latest analysis for BYD. Since these July figures were released on 2 August 2026, BYD’s share price has been under pressure in the short term, with a 1 day share price return of 2.82% lower and a 7...

Hong Kong is reworking its tax rules for traders, asset managers, and family offices, and that could reshape where capital and talent choose to work and invest next. Possible tax breaks on carried interest and performance pay are drawing fresh attention to locally listed financial services stocks that are closest to this shift. This article explores three Hong Kong financial and asset management stocks that are closely tied to these reforms and explains why their exposure to the news may be...

Beijing 51World Digital Twin Technology went into this earnings release with a hot stock and a cold income statement. The share price is up about 52% over the past three months, yet the latest half year still delivered a sizeable loss and kept the company in the red on a trailing twelve month basis. The core story today is margin pressure. Revenue now sits in the mid hundreds of millions of CNY, but trailing twelve month net income from continuing operations remains deeply negative and basic...

Xinyi Solar Holdings’ past announcement for the half year ended 30 June 2026 showed sales of CNY 8,430.11 million and net income of CNY 39.02 million, alongside an interim dividend of HK$0.0023 per share payable on 2 September 2026. The sharp drop in profit and reduced interim dividend highlight pressure on the company’s earnings power and its capacity to return cash to shareholders. Against this backdrop, we’ll explore how the profit compression and lower interim dividend reshape Xinyi...

Hang Lung Properties (SEHK:101) is back in focus after its first half 2026 results, which showed higher sales along with lower net income and earnings per share, as well as an affirmed interim dividend announcement. See our latest analysis for Hang Lung Properties. At a HK$7.48 share price, Hang Lung Properties has seen a 5.35% 1 month share price return but is still down 14.22% year to date, with the 1 year total shareholder return declining 2.42% and the 5 year total shareholder return...

Why Wanguo Gold Group’s latest profit guidance matters Wanguo Gold Group (SEHK:3939) issued fresh earnings guidance on 4 August 2026, projecting profit attributable to owners of RMB 880 million to RMB 920 million for the six months ended 30 June 2026. This guidance range compares with profit of about RMB 601 million for the same period in 2025, which the company states represents an increase of between 46.4% and 53.1%, with management linking the change mainly to business growth. See our...

Galaxy Entertainment Group (SEHK:27) has drawn fresh attention after partnering with Ant Bank (Macao) Limited to open the Galaxy Macau and Ant Bank Financial Services Station inside its integrated resort. See our latest analysis for Galaxy Entertainment Group. The partnership with Ant Bank comes as Galaxy Entertainment Group trades at HK$33.12, with a 30 day share price return of 5.21% but a year to date share price decline of 14.29%. Over the longer term, the 3 year total shareholder return...

Cutia Therapeutics ( HKG:2487 ) is possibly approaching a major achievement in its business, so we would like to shine...